BackgroundResting state functional connectivity (rsFC) offers promise for individualizing stimulation targets for transcranial magnetic stimulation (TMS) treatments. However current targeting approaches do not account for non-focal TMS effects or large scale connectivity patterns. To overcome these limitations, we propose a novel connectivity-based electric-field (e-field) modelling approach to identify optimal single-subject TMS targets using whole-brain rsFC.MethodsWe recruited 91 anxious misery (AM) patients and 25 controls. We measured depression symptoms via standard clinical questionnaires (MADRS/HAMD) and via a data-driven symptom clustering approach (Loss cluster) which used multiple items across 32 clinical measures. We also recorded rsFC in these individuals. We then used a Principal components analysis (PCA) regression to predict symptoms from rsFC and generate a slope vector (M) and intercept (b) for our e-field augmented model. We modeled 17 left dlPFC sites using 24 equally spaced coil orientations. We computed single-subject predicted ΔMADRS/HAMD and Δ Loss scores for each site/orientation combination according to the following equations: ΔMADRS/HAMD = MEX + b, and Δ Loss = MEX + b, where E represents a vectorized summary of the e-field model an X represents the single-subject rsFC matrix.ResultsIn AM patients, our model predicted a significant decrease in depression symptoms (measured by both MADRS/HAMD and Loss cluster) near BA46 for coil orientations perpendicular to the cortical gyrus. In control subjects, no site/orientation combination showed a significant relationship with MADRS/HAMD or Loss symptoms.DiscussionThese results replicate previous work demonstrating the efficacy of left dlPFC stimulation for depression treatment, and predict maximal efficacy near BA46. Importantly, our novel connectivity-based e-field modelling approach predicted a significant decrease in depression symptoms with more focal effects seen for the Loss cluster, and may be an effective way to identify potential TMS treatment responders, as well as to individualize TMS targeting to maximize the therapeutic impact.